Show simple item record

dc.contributor.author Lee, Sulggi
dc.contributor.authorByakwaga, Helen 
dc.contributor.author Boum, Yap
dc.contributor.author Burdo, Tricia H.
dc.contributor.authorWilliams, Kenneth C. 
dc.contributor.authorLederman, Michael M. 
dc.contributor.authorHuang, Yong 
dc.contributor.authorTracy, Russell P. 
dc.contributor.authorCao, Huyen 
dc.contributor.authorHaberer, Jessica E. 
dc.contributor.authorKembabazi, Annet 
dc.contributor.authorBangsberg, David R. 
dc.contributor.authorMartin, Jeffrey N. 
dc.contributor.authorHunt, Peter W. 
dc.date.accessioned2024-02-27T09:37:45Z
dc.date.available2024-02-27T09:37:45Z
dc.date.issued2017
dc.identifier.citationLee, S., Byakwaga, H., Boum, Y., Burdo, T. H., Williams, K. C., Lederman, M. M., ... & Hunt, P. W. (2017). Immunologic pathways that predict mortality in HIV-infected Ugandans initiating antiretroviral therapy. The Journal of infectious diseases, 215(8), 1270-1274.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/3433
dc.description.abstractThe plasma kynurenine/tryptophan (KT) ratio, a marker of adaptive immune defects, strongly predicts mortality during treated human immunodeficiency virus (HIV) disease in Ugandans as compared to US-based populations. Here, the KT ratio and T-cell and plasma biomarkers of immune activation were measured among 535 HIV-infected Ugandans prior to ART initiation and at month 6 of viral suppression. The month 6 KT ratio (adjusted hazard ratio [aHR], 2.74), soluble CD14 level (aHR, 2.32), interleukin 6 level (aHR, 2.34), and D-dimer level (aHR, 1.95) were associated with mortality occurring ≥6 months after ART initiation. The KT ratio remained significantly predictive of mortality even after adjustment for the additional biomarkers, suggesting an independent contribution to clinical outcomes in resource-limited settings.en_US
dc.description.sponsorshipNational Institutes of Health (grants R56AI100765, R21AI087035, R01AI087145, R01MH054907, P01AI076174, K23GM112526, and P30AI036219), the University of California–San Francisco (UCSF)/Gladstone Institute of Virology and Immunology Center for AIDS Research (grant P30AI027763), the UCSF Clinical and Translational Research Institute Clinical Research Center (grant UL1RR024131), the Center for AIDS Prevention Studies (grant P30MH62246), and the AIDS Cancer Specimen Resource (grant UM1 CA181255)en_US
dc.language.isoen_USen_US
dc.publisherThe Journal of infectious diseasesen_US
dc.subjectHIVen_US
dc.subjectKynurenineen_US
dc.subjectTryptophanen_US
dc.subjectD-dimeren_US
dc.subjectIL-6en_US
dc.subjectsCD14en_US
dc.subjectMortalityen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectAfricaen_US
dc.titleImmunologic Pathways That Predict Mortality in HIV-Infected Ugandans Initiating Antiretroviral Therapyen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Research Articles [432]
    These are different research articles about different Scholars

Show simple item record